Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
← catalyst calendarSponsored by Rallybio (industry) · RLYB — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
16actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-14 | actual | When the study began enrolling |
| Primary completion | 2026-02-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematologic Diseases
- Autoimmune Diseases
Intervention
- Drug: RLYB116 for Injection
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment related adverse events as defined by CTCAE 5.0.
measured From baseline to Day 1, 2, 3, 4, 5, 8, 9, 15, 16, 22, 23, 29, 30, 32, 33, 36, 43, 57, 71, 99
Permalink · RLYB's whole pipeline · Catalyst calendar · Every registered study · What changed